Profound Medical (TSE:PRN) Stock Price Down 2.6% – What’s Next?

Profound Medical Corp. (TSE:PRN)’s stock price traded down 2.6% during mid-day trading on Friday . The company traded as low as C$8.98 and last traded at C$9.07. 12,867 shares traded hands during mid-day trading, an increase of 11% from the average session volume of 11,629 shares. The stock had previously closed at C$9.31.

Profound Medical Stock Performance

The business has a 50-day moving average of C$8.38 and a two-hundred day moving average of C$7.72. The company has a debt-to-equity ratio of 20.05, a current ratio of 6.12 and a quick ratio of 14.98. The company has a market cap of C$273.86 million, a P/E ratio of -6.87 and a beta of -0.91.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, November 13th. The company reported C$0.26 EPS for the quarter. Profound Medical had a negative net margin of 349.41% and a negative return on equity of 85.22%. The business had revenue of C$7.36 million during the quarter. On average, sell-side analysts predict that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.